Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
Has R&D productivity increased since last year’s analysis? Who are the new entrants into the elite top five group, and who has dropped out? Have the positive innovation dynamics of recent years continued? (Also see "Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers" - In Vivo, 18 December, 2015.)
Our annual survey suggests that the fundamental innovation performance of our sample of top 30 companies has improved considerably since...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
